1) Welcome and Rollcall
   I. Welcome
   Meeting opened by Sandra Robinson, ADAP Branch Chief

   II. Rollcall
   MAC Members in Attendance

   MAC Members not in Attendance
   Jennefer Yoon, Laveeza Bhatti

   Magellan Representatives in Attendance
   Kristen Haloski

   Magellan Representatives not in Attendance
   Jason Eugenio, Nicole Quackenbush

   CDPH/Office of AIDS staff in Attendance
   Philip Peters, Sandra Robinson, Cynthia Reed-Aguayo, Marisa Ramos, Becca Parks

   CDPH/Office of AIDS staff not in Attendance
   N/A

2) ADAP / MAC Updates
   I. Medications Added to the ADAP Formulary
   Dr. Peters announced:
   • Oseltamivir (Tamiflu®) was added to the ADAP formulary on July 29, 2020.
   • Lamivudine/tenofovir disoproxil fumarate (Temixys™), which contains the same ingredients as Cimduo® which is already listed on the ADAP formulary was added to the ADAP formulary on September 10, 2020 adding that Temixys™ was added to ensure clients received coverage regardless of the brand medication (Cimduo® or Temixys™) clients may be prescribed.

   II. Medications Removed from the Formulary
   Dr. Peters announced the removal of three non-antiretroviral medications from the ADAP formulary effective on September 10, 2020. Rosiglitazone, removed as there are multiple safer options listed on the formulary; clofazimine, removed because it is no longer available in the U.S.; and trimetrexate, removed because the drug is no longer manufactured.

   III. Update on the Medications Discussed During the July 2020 MAC Meeting
   Dr. Peters provided the following updates:
   • Fostemsavir was added to the ADAP formulary on September 22, 2020 noting that prescription would require the use of a prior authorization.
• ADAP is waiting U.S. Food and Drug Administration approval of long-acting, injectable cabotegravir and rilpivirine (Cabenuva®) and the related oral cabotegravir tablet. While waiting the approval, ADAP is working on development of the process to make the long-acting treatment available to clients.

• ADAP is awaiting a cost analysis to be completed for amoxicillin-clavulanate (Augmentin™), once complete, ADAP will request authorization to add amoxicillin-clavulanate to the ADAP formulary.

Dr. Peters also informed the MAC that ADAP management received a formulary review presentation focused on medications used to treat Major Depressive Disorder and Anxiety Disorder. Several medications were identified as gaps in the formulary and ADAP has requested cost analyses on medications to treat these disorders.

3) **Medication Discussion**
There were no new FDA approved antiretroviral medications listed for discussion during this meeting.

4) **Opportunistic Infection Treatments**
There were no opportunistic infection medications listed for discussion during this meeting.

5) **Magellan RX Presentation**
   1. Presentation/Discussion
      o Insulin
      After the presentation, the pricing of insulin was mentioned as a concern and members indicated that ADAP should consider the cost if the program moves forward with adding insulin. The members also recommended that ADAP should also consider adding the test strips if insulin will be added to the formulary.

      o Hypertension Medications
      No questions or comments

      o Medication Assisted Treatment (MAT)
      A correction was mentioned during the presentation identifying that the brand name Evzio® injectable naloxone, as listed on the presentation, is not on the ADAP formulary but the generic injectable naloxone is on formulary. ADAP MAC members provided the following input:
      • Members voiced concern regarding ADAP clients’ high utilization of opioids.
      • Alternative medications for pain treatment would be beneficial.

      At the request of the MAC, Dr. Peters provided an overview of the process for adding medications to the ADAP formulary.
6) **Close of Meeting**

   I. Announcement of January Meeting Date and Time

   Sandra Robinson announced the next ADAP MAC meeting is scheduled for January 20, 2021 from 7:30 am to 9:00 am.